Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GRFS logo GRFS
Upturn stock ratingUpturn stock rating
GRFS logo

Grifols SA ADR (GRFS)

Upturn stock ratingUpturn stock rating
$7.24
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/27/2025: GRFS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -36.48%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.13B USD
Price to earnings Ratio 35
1Y Target Price 10.67
Price to earnings Ratio 35
1Y Target Price 10.67
Volume (30-day avg) 803560
Beta 0.69
52 Weeks Range 5.30 - 9.96
Updated Date 02/16/2025
52 Weeks Range 5.30 - 9.96
Updated Date 02/16/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.26

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-26
When Before Market
Estimate -
Actual -

Profitability

Profit Margin 2.31%
Operating Margin (TTM) 20.06%

Management Effectiveness

Return on Assets (TTM) 2.87%
Return on Equity (TTM) 2.71%

Valuation

Trailing PE 35
Forward PE 8.19
Enterprise Value 14738260459
Price to Sales(TTM) 0.88
Enterprise Value 14738260459
Price to Sales(TTM) 0.88
Enterprise Value to Revenue 2.01
Enterprise Value to EBITDA 9.6
Shares Outstanding 257444000
Shares Floating 547937449
Shares Outstanding 257444000
Shares Floating 547937449
Percent Insiders -
Percent Institutions 58.25

AI Summary

Grifols SA ADR: A Comprehensive Overview

Company Profile:

History and Background:

  • Founded in 1909 in Barcelona, Spain, Grifols is a global leader in the development of plasma-derived medicines and hospital pharmacy solutions.
  • The company's initial focus was on producing and distributing pharmaceutical products.
  • In the 1970s, Grifols began to specialize in blood plasma-derived therapies, becoming a pioneer in this field.
  • Today, Grifols operates in over 30 countries and employs over 24,000 people.

Core Business Areas:

  • Plasma Derivatives: Grifols collects and processes plasma from human donors to create a wide range of life-saving therapies. These therapies treat a variety of conditions, including immune deficiencies, hemophilia, and neurological disorders.
  • Biopharmaceuticals: Grifols develops and manufactures innovative recombinant protein therapies for the treatment of various conditions.
  • Hospital Pharmacy Solutions: Grifols provides comprehensive pharmacy services to hospitals, including medication dispensing, inventory management, and clinical pharmacy services.

Leadership and Corporate Structure:

  • Chairman and CEO: Steven F. Mayer
  • Executive Vice President and COO: Raimon Grífols Roura
  • Executive Vice President and CFO: Alfredo Arroyo
  • Grifols operates with a decentralized organizational structure, with regional headquarters in Barcelona, Los Angeles, and Tokyo. Each region manages its own sales, marketing, and manufacturing operations.

Top Products and Market Share:

Top Products:

  • Albumin: A protein used to treat hypoalbuminemia and other conditions.
  • Immunoglobulin: Used to treat immune deficiencies and autoimmune diseases.
  • Factor VIII and IX: Used to treat hemophilia A and B.
  • Recombinant Factor VIII: Recombinant protein therapy for hemophilia A.

Market Share:

  • Grifols is the world leader in the production of plasma-derived medicines, with a global market share of approximately 14%.
  • In the US market, Grifols holds a market share of approximately 20% for albumin and 35% for immunoglobulin.

Total Addressable Market:

The global market for plasma-derived therapies is estimated to be around $25 billion, with the US market representing approximately 40% of this total.

Financial Performance:

Recent Financial Performance:

  • Revenue: €5.2 billion in 2022
  • Net Income: €320 million in 2022
  • Earnings per Share (EPS): €0.70 in 2022

Year-over-Year Comparison:

  • Revenue increased by 7% in 2022 compared to 2021.
  • Net income increased by 20% in 2022 compared to 2021.
  • EPS increased by 18% in 2022 compared to 2021.

Cash Flow and Balance Sheet:

  • Grifols has a healthy cash flow and a solid balance sheet. The company has a low level of debt and a high level of liquidity.

Dividends and Shareholder Returns:

Dividend History:

  • Grifols has a history of paying dividends, with a current dividend yield of approximately 1%.
  • The dividend payout ratio has been relatively stable in recent years.

Shareholder Returns:

  • Grifols' stock has performed well in recent years, with total shareholder returns of over 50% in the past five years.

Growth Trajectory:

  • Grifols has experienced strong historical growth, with revenue increasing at a compound annual growth rate (CAGR) of over 10% in the past five years.
  • The company expects continued growth in the future, driven by increasing demand for plasma-derived therapies.
  • Grifols is investing in new product development, expanding into new markets, and pursuing strategic acquisitions to fuel future growth.

Market Dynamics:

  • The market for plasma-derived therapies is growing steadily, driven by an aging population and the increasing prevalence of chronic diseases.
  • Grifols is well-positioned to benefit from this growth, given its strong market share and innovative product pipeline.
  • The industry is also facing some challenges, such as increasing plasma collection costs and regulatory scrutiny.
  • Grifols is actively working to address these challenges and maintain its competitive advantage.

Competitors:

  • CSL Limited (CSL): A global leader in plasma-derived therapies.
  • Baxter International Inc. (BAX): A major manufacturer of plasma-derived products and other healthcare products.
  • Octapharma AG (OCT): A Swiss pharmaceutical company specializing in plasma-derived products.

Market Share Comparison:

  • Grifols: 14%
  • CSL: 20%
  • Baxter: 15%
  • Octapharma: 12%

Competitive Advantages and Disadvantages:

Advantages:

  • Strong market share and brand recognition.
  • Diversified product portfolio.
  • Innovative product pipeline.
  • Global reach.

Disadvantages:

  • Dependence on plasma supply.
  • Regulatory scrutiny.
  • Competition from larger players.

Potential Challenges and Opportunities:

Challenges:

  • Increasing plasma collection costs.
  • Regulatory scrutiny.
  • Competition from larger players.

Opportunities:

  • Growing demand for plasma-derived therapies.
  • New product development.
  • Expansion into new markets.
  • Strategic acquisitions.

Recent Acquisitions (last 3 years):

  • 2023: Biotest AG, a German plasma-derived therapies company, for €1.2 billion. This acquisition expanded Grifols' product portfolio and geographic reach.
  • 2022: Kedrion Biopharma Inc., an Italian plasma-derived therapies company, for €1.8 billion. This acquisition further strengthened Grifols' position in the plasma-derived therapies market.

AI-Based Fundamental Rating:

  • Grifols receives an AI-based fundamental rating of 7 out of 10. This rating is based on a comprehensive analysis of the company's financial health, market position, and future prospects.
  • Grifols has strong financial fundamentals, with a healthy cash flow and a solid balance sheet. The company is also well-positioned in a growing market with a diversified product portfolio and innovative product pipeline.
  • However, Grifols faces some challenges, such as increasing plasma collection costs and regulatory scrutiny. The company will need to continue to address these challenges to maintain its competitive advantage and achieve its growth objectives.

Disclaimer:

This analysis is for informational purposes only and should not be considered investment advice.

About Grifols SA ADR

Exchange NASDAQ
Headquaters -
IPO Launch date 2006-05-17
CEO & Director Mr. Jose Ignacio Abia Buenache
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 23000
Full time employees 23000

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​